It was always the suspicion. When shadowy pharmacy middlemen started in 2019 to create yet another layer of middlemen, critics suspected they would be used to avoid transparency and skim even more money from the interstices of arcane — but wildly lucrative — drug transactions.
Now evidence is accumulating that it might be happening. Two government investigations this year accused the giant health conglomerates that own the middlemen of doing precisely that: hiding millions that were supposed to go to payers and pocketing the money themselves...
Comments